Rapidly increasing usage of TRT in the absence of good scientific data is the impetus for the formation of a multidisciplinary task force, led by the Institute of Medicine and supported by the NIA. The task force will make recommendations about the design, safety, and ethics of clinical trials to evaluate the risks and benefits of TRT, including whether such studies are even warranted. The AACE recently updated its guidelines for the treatment and evaluation of hypogonadism. The updated guidelines are intended to serve as a source of guidance for healthcare professionals. The document is also an appeal to clinicians to increase their awareness of hypogonadism, and to discuss the issue with their at-risk patients.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.
2 Clarke Drive
Cranbury, NJ 08512